

## Accepted Manuscript

Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial

Freddy Abnoui, Vandana Sundaram, Celina M. Yong, Jayne Prats, Efthymios N. Deliargyris, Gregg W. Stone, Christian W. Hamm, Ph. Gabriel Steg, C. Michael Gibson, Harvey D. White, Matthew J. Price, Philippe G n reux, Manisha Desai, Lingyao Yang, Victoria Y. Ding, Robert A. Harrington, Deepak L. Bhatt, Kenneth W. Mahaffey

PII: S0002-8703(17)30079-0  
DOI: doi: [10.1016/j.ahj.2017.02.031](https://doi.org/10.1016/j.ahj.2017.02.031)  
Reference: YMJJ 5398

To appear in: *American Heart Journal*

Received date: 1 September 2016  
Accepted date: 28 February 2017

Please cite this article as: Abnoui Freddy, Sundaram Vandana, Yong Celina M., Prats Jayne, Deliargyris Efthymios N., Stone Gregg W., Hamm Christian W., Steg Ph. Gabriel, Gibson C. Michael, White Harvey D., Price Matthew J., G n reux Philippe, Desai Manisha, Yang Lingyao, Ding Victoria Y., Harrington Robert A., Bhatt Deepak L., Mahaffey Kenneth W., Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial, *American Heart Journal* (2017), doi: [10.1016/j.ahj.2017.02.031](https://doi.org/10.1016/j.ahj.2017.02.031)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Cangrelor reduces the risk of ischemic complications in patients with single and multi-vessel disease undergoing PCI: insights from the CHAMPION PHOENIX Trial**

Freddy Abnoui<sup>1</sup>, Vandana Sundaram<sup>2</sup>, Celina M. Yong<sup>1</sup>, Jayne Prats<sup>3</sup>, Efthymios N. Deliargyris<sup>3</sup>, Gregg W. Stone,<sup>4</sup> Christian W. Hamm,<sup>5</sup> Ph. Gabriel Steg,<sup>6</sup> C. Michael Gibson,<sup>7</sup> Harvey D. White,<sup>8</sup> Matthew J. Price,<sup>9</sup> Philippe Généreux,<sup>4</sup> Manisha Desai,<sup>2</sup> Lingyao Yang<sup>2</sup>, Victoria Y. Ding<sup>2</sup>, Robert A. Harrington<sup>1</sup>, Deepak L. Bhatt,<sup>10</sup> Kenneth W. Mahaffey<sup>1</sup>

RCT# NCT01156571

<sup>1</sup>Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine

<sup>2</sup>Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine

<sup>3</sup>The Medicines Company, Parsippany, New Jersey

<sup>4</sup>Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York;

<sup>5</sup>Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany;

<sup>6</sup>DHU (Département Hospitalo-Universitaire)-FIRE (Fibrosis, Inflammation, REmodelling), Hôpital Bichat, AP-HP (Assistance Publique – Hôpitaux de Paris), Université Paris-Diderot, Sorbonne - Paris Cité, and FACT (French Alliance for Cardiovascular clinical Trials), an F-CRIN network, INSERM U-1148, Paris, France; the NLHI, ICMS, Royal Brompton Hospital, Imperial College, London, United Kingdom;

<sup>7</sup>Beth Israel Deaconess Medical Center, Division of Cardiology, Harvard Medical School Boston, Boston, Massachusetts;

<sup>8</sup>University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.);

<sup>9</sup>Scripps Clinic and Scripps Translational Science Institute, La Jolla, California;

<sup>10</sup>Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts.

The CHAMPION PHOENIX trial was funded by The Medicines Company.

Dr. Abnoui has no disclosures.

Dr. Yong has no disclosures.

Dr. Stone has no disclosures.

Dr. Hamm discloses honoraria from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, SanofiAventis, Pfizer and The Medicines Company.

Download English Version:

<https://daneshyari.com/en/article/5594421>

Download Persian Version:

<https://daneshyari.com/article/5594421>

[Daneshyari.com](https://daneshyari.com)